PT  - JOURNAL ARTICLE
AU  - Salwa Naushin
AU  - Viren Sardana
AU  - Rajat Ujjainiya
AU  - Nitin Bhatheja
AU  - Rintu Kutum
AU  - Akash Kumar Bhaskar
AU  - Shalini Pradhan
AU  - Satyartha Prakash
AU  - Raju Khan
AU  - Birendra Singh Rawat
AU  - Karthik Bharadwaj Tallapaka
AU  - Mahesh Anumalla
AU  - Giriraj Ratan Chandak
AU  - Amit Lahiri
AU  - Susanta Kar
AU  - Shrikant Ramesh Mulay
AU  - Madhav Nilakanth Mugale
AU  - Mrigank Srivastava
AU  - Shaziya Khan
AU  - Anjali Srivastava
AU  - Bhawna Tomar
AU  - Murugan Veerapandian
AU  - Ganesh Venkatachalam
AU  - Selvamani Raja Vijayakumar
AU  - Ajay Agarwal
AU  - Dinesh Gupta
AU  - Prakash M Halami
AU  - Muthukumar Serva Peddha
AU  - Gopinath M Sundaram
AU  - Ravindra P Veeranna
AU  - Anirban Pal
AU  - Vinay Kumar Agarwal
AU  - Anil Ku Maurya
AU  - Ran Vijay Kumar Singh
AU  - Ashok Kumar Raman
AU  - Suresh Kumar Anandasadagopan
AU  - Parimala Karuppanan
AU  - Subramanian Venkatesan
AU  - Harish Kumar Sardana
AU  - Anamika Kothari
AU  - Rishabh Jain
AU  - Anupma Thakur
AU  - Devendra Singh Parihar
AU  - Anas Saifi
AU  - Jasleen Kaur
AU  - Virendra Kumar
AU  - Avinash Mishra
AU  - Iranna Goger
AU  - Geethavani Rayasam
AU  - Praveen Singh
AU  - Rahul Chakraborty
AU  - Gaura Chaturvedi
AU  - Pinreddy Karunakar
AU  - Rohit Yadav
AU  - Sunanda Singhmar
AU  - Dayanidhi Singh
AU  - Sharmistha Sarkar
AU  - Purbasha Bhattacharya
AU  - Sundaram Acharya
AU  - Vandana Singh
AU  - Shweta Verma
AU  - Drishti Soni
AU  - Surabhi Seth
AU  - Shakshi Vashisht
AU  - Sarita Thakran
AU  - Firdaus Fatima
AU  - Akash Pratap Singh
AU  - Akanksha Sharma
AU  - Babita Sharma
AU  - Manikandan Subramanian
AU  - Yogendra Padwad
AU  - Vipin Hallan
AU  - Vikram Patial
AU  - Damanpreet Singh
AU  - Narendra Vijay Tirpude
AU  - Partha Chakrabarti
AU  - Sujay Krishna Maity
AU  - Dipyaman Ganguly
AU  - Jit Sarkar
AU  - Sistla Ramakrishna
AU  - Balthu Narender Kumar
AU  - A Kiran Kumar
AU  - Sumit G. Gandhi
AU  - Piyush Singh Jamwal
AU  - Rekha Chouhan
AU  - Vijay Lakshmi Jamwal
AU  - Nitika Kapoor
AU  - Debashish Ghosh
AU  - Ghanshyam Thakkar
AU  - Umakanta Subudhi
AU  - Pradip Sen
AU  - Saumya Ray Chaudhury
AU  - Rashmi Kumar
AU  - Pawan Gupta
AU  - Amit Tuli
AU  - Deepak Sharma
AU  - Rajesh P. Ringe
AU  - Amarnarayan D
AU  - Mahesh Kulkarni
AU  - Dhanasekaran Shanmugam
AU  - Mahesh S Dharne
AU  - Syed G. Dastager
AU  - Rakesh Joshi
AU  - Amita P. Patil
AU  - Sachin N. Mahajan
AU  - Abu Junaid Khan
AU  - Vasudev Wagh
AU  - Rakeshkumar Yadav
AU  - Ajinkya Khilari
AU  - Mayuri Bhadange
AU  - Arvindkumar H. Chaurasiya
AU  - Shabda E Kulsange
AU  - Krishna Khairnar
AU  - Shilpa Paranjape
AU  - Jatin Kalita
AU  - G. Narahari Sastry
AU  - Tridip Phukan
AU  - Prasenjit Manna
AU  - Wahengbam Romi
AU  - Pankaj Bharali
AU  - Dibyajyoti Ozah
AU  - Ravi Kumar Sahu
AU  - Elapavalooru V.S.S.K. Babu
AU  - Rajeev Sukumaran
AU  - Aiswarya R Nair
AU  - Prajeesh Kooloth-Valappil
AU  - Anoop Puthiyamadam
AU  - Adarsh Velayudhanpillai
AU  - Kalpana Chodankar
AU  - Samir Damare
AU  - Yennapu Madhavi
AU  - Ved Varun Aggarwal
AU  - Sumit Dahiya
AU  - Anurag Agrawal
AU  - Debasis Dash
AU  - Shantanu Sengupta
TI  - Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV-2
AID  - 10.1101/2021.01.12.21249713
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.12.21249713
4099  - http://medrxiv.org/content/early/2021/02/28/2021.01.12.21249713.short
4100  - http://medrxiv.org/content/early/2021/02/28/2021.01.12.21249713.full
AB  - To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India), conducted a sero-survey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS CoV2 anti-nucleocapsid (anti-NC) antibodies; 95% with surrogate neutralization activity. Three-fourth recalled no symptoms. Repeat serology tests at 3 (n=346) and 6 (n=35) months confirmed stability of antibody response and neutralization potential. Local sero-positivity was higher in densely populated cities and was inversely correlated with a 30 day change in regional test positivity rates (TPR). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of sero-positivity were high-exposure work (Odds Ratio, 95% CI, p value; 2·23, 1·92–2·59, 6·5E-26), use of public transport (1·79, 1·43–2·24, 2·8E-06), not smoking (1·52, 1·16–1·99, 0·02), non-vegetarian diet (1·67, 1·41–1·99, 3·0E-08), and B blood group (1·36,1·15-1·61, 0·001).Impact Statement Widespread asymptomatic and undetected SARS-CoV2 infection affected more than a 100 million Indians by September 2020. Declining new cases thereafter may be due to persisting humoral immunity amongst sub-communities with high exposure.Funding Council of Scientific and Industrial Research, India (CSIR)Competing Interest StatementThe authors have declared no competing interest.Funding StatementCouncil of Scientific and Industrial Research, India (CSIR) The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CSIR IGIB: Institutional Ethical CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified categorized data of the participants can be provided on request basis after approval of ethics committee of the institute/organisation to which the requesting person belongs, stating the potential need and usage and signing of an agreement with the corresponding authors on behalf of CSIR IGIB. The request could be made to the corresponding authors after 90 days of publication.